Agilent Technologies Inc (NYSE:A) target price raised to $52.00, issued a report today by Zacks Investment Research
- Updated: October 5, 2016
Just yesterday Agilent Technologies Inc (NYSE:A) traded 0.73% higher at $47.14. Agilent Technologies Inc’s 50-day moving average is $46.66 and its 200-day moving average is $44.63. With the last stock close price up 5.69% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Trade Volume was down over the average, with 408,944 shares of A changing hands under the typical 1,853,450
Agilent Technologies Inc (NYSE:A) had its target price raised to $52.00 by Zacks Investment Research in a report released Wednesday October 05, 2016. The new target price indicates a possible upside of 0.10% based on the company's last stock close price.
Recent Performance Chart
Agilent Technologies Inc has PE ratio of 32.71 with a one year low of $34.15 and a one year high of $48.63 and has a market capitalization of $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 14 brokers have issued a research note on the company. The average stock price target is $45.86 with 6 brokers rating the stock a strong buy, 4 brokers rating the stock a buy, 6 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Agilent Technologies Inc (NYSE:A)
Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.